Skip to main content

Month: August 2025

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced selection of a novel modified release oral formulation for enobosarm, a selective androgen receptor modulator, for chronic weight loss management, following confirmation of pharmacokinetic endpoints in a clinical study. The single dose, open label pilot study evaluated the plasma concentration versus time profile of a proprietary, patentable modified release formulation of enobosarm 3mg. The new formulation demonstrated the intended distinct target product release profile, which includes a reduction in maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a...

Continue reading

SEALSQ Unveils SEALQuantum.com Innovation Lab Progress, Expanding into AI to Anticipate the Convergence with Quantum and Cybersecurity

Geneva, Switzerland, Aug. 11, 2025 (GLOBE NEWSWIRE) — With a total $30 Million investment capacity, SEALSQ shares strategic updates on ColibriTD and IC’Alps SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a leading provider of Semiconductors, PKI, and Post-Quantum technology hardware and software products, today unveiled the progress of its SEALQuantum.com Lab, a next-generation research and development hub focused on the convergence of quantum computing, and cybersecurity now Expanding into artificial intelligence (AI). With a total of $30 Million investment capacity, the Lab has already invested in quantum technology startups like ColibriTD and made the acquisition of semiconductor design service specialist IC’ALPS to develop tailor made advanced solutions for semiconductor manufacturing and post-quantum...

Continue reading

Amaze Forms Strategic Partnership with Parler Cloud Technologies, the Parent Company of Pulse, and Announces $6 Million Above-Market Investment by Parler

Collaboration Integrates Amaze’s E-Commerce Platform into Parler’s Social Media Ecosystem; Investment Underscores Confidence and Value in Amaze’s Creator-First Model NEWPORT BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze”) a global leader in creator-powered commerce, today announced a strategic partnership with Parler Cloud Technologies (“Parler”), the parent company of Pulse, and an above-market investment by Parler to purchase common stock and warrants of Amaze. The exclusive partnership will integrate Amaze’s e-commerce platform into Parler’s social media properties, including PlayTV and Parler.com. The integration will enable creators to sell products directly through Parler’s growing network, furthering Amaze’s mission to power creator monetization at scale. The investment...

Continue reading

General Timothy Ray, USAF (ret) Joins Critical Metals Corp’s Advisory Board

NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) — Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced that General Tim Ray, USAF (ret) joined the Company’s newly formed Advisory Board, which will help Critical Metals Corp’s Board of Directors and executive management team as the Company develops its portfolio of critical minerals projects. The Advisory Board includes Christian Aramayo and Mathew August. “As Critical Metals Corp advances the Tanbreez project in southern Greenland for the benefit of North America and Europe, the security and defense contributions of these rare earth elements will ensure we can rapidly disengage from China,” said Tony Sage, CEO and Executive Chairman of Critical Metals Corp. “We are delighted that someone of General Ray’s...

Continue reading

Callinex to Change Name to Visionary Copper and Gold Mines Inc.

VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) — Callinex Mines Inc. (the “Company” or “Callinex”) (TSX-V: CNX; OTCQX: CLLXF) is pleased to announce that it plans to change its name to “Visionary Copper and Gold Mines Inc.” (the “Name Change”). The Name Change better reflects the Company’s forward-looking commitment to creating value through the discovery and development of sustainable copper and gold mines across Canada. The name Callinex has been a cornerstone of our identity, deeply rooted in our proud history in Manitoba. It has provided a strong foundation, guiding us through years of growth and many of our greatest achievements. As we move forward, the new name, Visionary Copper and Gold Mines Inc., embodies our long-term vision to lead in sustainable mining, delivering lasting value to our stakeholders and communities...

Continue reading

EverQuote Announces $21 Million Repurchase of Shares from Link Ventures and Affiliated Entities Controlled by Chairman and Co-Founder, David Blundin

Enables EverQuote to efficiently execute a portion of its $50 million Share Repurchase Program Mr. Blundin remains EverQuote’s Chairman and largest shareholderCAMBRIDGE, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced that it has agreed to repurchase an aggregate of 900,000 shares of its Class A common stock, resulting in an aggregate repurchase price of $21 million (the “Repurchase”) from Link Ventures, which is an entity affiliated with funds advised by David Blundin, EverQuote’s Chairman and Co-Founder, and other affiliated entities of Mr. Blundin. The transaction was executed on a price per share of $23.33, which represents a 1.75% discount to Friday’s closing price and a 3.96% discount on the Company’s 10-day volume-weight average price on August...

Continue reading

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

COPENHAGEN, Denmark, August 11, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2025 financial results on Thursday August 14, 2025, before opening of the Nasdaq CM. Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event. To join the webcast, please click...

Continue reading

Schouw & Co. share buy-back programme, week 32 2025

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 1 August 2025 87,500 594.60 52,027,522    Monday, 4 August 2025 1,300 616.35 801,255    Tuesday, 5 August 2025 1,300 616.64 801,632    Wednesday, 6 August 2025 1,300 618.26 803,738    Thursday, 7 August 2025 1,000 623.46 623,460    Friday,...

Continue reading

Lincoln Educational Services Reports Second Quarter Results and Increases Outlook for Full Year 2025

Conference Call Today at 10:00 a.m. Eastern Daylight Time PARSIPPANY, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (Nasdaq: LINC) today announced financial and operating results for the second quarter ended June 30, 2025, as well as recent business developments. Second Quarter 2025 Financial and Operational Highlights(Quarter ended June 30, 2025, compared to June 30, 2024, unless otherwise noted) Financial PerformanceRevenue of $116.5 million, an increase of 13.2%, 15.1% excluding the Transitional segment Adjusted EBITDA of $10.5 million, an increase of 68.4% Net income of $1.6 million, compared to $0.7 million net loss Based on strong first half performance and favorable operating trends, guidance for 2025 has been raisedStudent Metrics*Student starts up by 19.5%, or 21.8% excluding the...

Continue reading

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

– Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented at the European Society for Medical Oncology (ESMO) 2025 Congress in October – – VCN-01 demonstrates potential in retinoblastoma with Phase 1 safety and clinical outcome data presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting – – Cash and cash equivalents of $12.1 million as of June 30, 2025, expected cash runway into Q1 2026 – ROCKVILLE, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2025,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.